Nxera Pharma Stock Price, News & Analysis
Company Description
Nxera Pharma (OTC Link: SOLTF) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $618.5M.
SOLTF stock has gained 14.6% over the past year. Shares last traded at $6.30.
This page provides a comprehensive overview of SOLTF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Nxera Pharma (SOLTF) stock last traded at $6.30. Over the past 12 months, the stock has gained 14.6%. At a market capitalization of $618.5M, SOLTF is classified as a small-cap stock with approximately 90.5M shares outstanding.
Latest News
Nxera Pharma has 8 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. Key topics include earnings, AI, clinical trial, management. View all SOLTF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Nxera Pharma (SOLTF) currently stands at 1.5 million shares, down 13.8% from the previous reporting period, representing 1.9% of the float. Over the past 12 months, short interest has decreased by 15.3%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Nxera Pharma (SOLTF) currently stands at 1000.0 days. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges.
SOLTF Company Profile & Sector Positioning
Nxera Pharma (SOLTF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing SOLTF often look at related companies in the same sector, including Pharming Group (PHGUF), Oxford Biomedica (OXBDF), Sanbio (SNBOY), Northwest Bio (NWBO), and Cytodyn Inc (CYDY). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SOLTF's relative position within its industry.